May 14, 2008 - PLC Systems Inc. said it is demonstrating its RenalGuard System May 12-16 at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in Barcelona, Spain.

RenalGuard is based on existing preclinical study data that suggests initiating and maintaining high urine output during imaging procedures allows the body to rapidly eliminate toxins in contrast media, reducing their harmful effects. RenalGuard is a fully-automated, real-time matched fluid replacement device intended for interventional cardiology and radiology patients undergoing imaging procedures using contrast media.

PLC received the CE Mark Certificate for the RenalGuard System in December 2007, and concluded its pilot safety trial in the U.S. late in 2007. The company has received conditional approval from the FDA to commence a U.S. trial to study the effectiveness of RenalGuard in the prevention of CIN. In March 2008, PLC signed its first international distribution agreement for RenalGuard with Artech s.r.l., Cavezzo, Italy for distribution of its RenalGuard System into Italy.

About 7 million patients worldwide undergo interventional cardiovascular therapeutic and diagnostic imaging procedures each year. Contrast-induced nephropathy, or CIN, is a growing problem due to the increasing number of older patients, diabetics and patients with pre-existing renal failure - all of whose conditions make them at risk for CIN when they require interventional procedures that use radiographic contrast media. CIN is the third most common cause of in-hospital acute renal failure. It is associated with significant in-hospital mortality rates, and increases in long-term mortality rates, major in-hospital adverse cardiac events, and the risk of having to undergo renal dialysis therapy. Any of these can result in prolonged hospital stays and increased medical costs. Studies indicate between 15 and 20 percent of all patients undergoing image-guided cardiology and radiology procedures are at risk of developing CIN.

For more information: www.plcmed.com


Related Content

News | Image Guided Radiation Therapy (IGRT)

June 25, 2025 — Royal Philips and Indiana-based Methodist Hospitals recently announced the healthcare provider’s ...

Time June 25, 2025
arrow
News | PET-CT

June 23, 2025 — GE HealthCare’s commitment to advancing precision care in cardiology through its molecular imaging ...

Time June 23, 2025
arrow
News | Cardiac Imaging

May 20, 2025 — Royal Philips has launched the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter ...

Time May 27, 2025
arrow
News | Pediatric Imaging

May 13, 2025-- GE HealthCare recently announced the U.S. Food and Drug Administration (FDA) has approved a pediatric ...

Time May 20, 2025
arrow
News | Ultrasound Imaging

May 14, 2025 — A comprehensive new study based on nationwide claims data from more than 11 million patients shows that ...

Time May 14, 2025
arrow
News | Cardiac Imaging

April 30, 2025 – Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has launched Viz ...

Time May 02, 2025
arrow
News | Artificial Intelligence

April 16, 2025 — An artificial intelligence (AI) program trained to review images from a common medical test can detect ...

Time April 16, 2025
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | Radiology Imaging

July 23, 2024 — EMVision, an Australian medical device company focused on the development and commercialization of ...

Time July 23, 2024
arrow
News | Radiology Business

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
Subscribe Now